Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Head and Neck Cancer Clinical Trials

23 recruiting trials for Head and Neck Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
23
Total Trials
23
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03702309

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor...

Sponsor: University Health Network, TorontoEnrolling: 25001 location
RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGPhase 1NCT04999761

AB122 Platform Study

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each...

Sponsor: Taiho Pharmaceutical Co., Ltd.Enrolling: 9179 locations
RECRUITINGPhase 1 / Phase 2NCT04930432

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic...

Sponsor: Betta Pharmaceuticals Co., Ltd.Enrolling: 40020 locations
RECRUITINGPhase 1NCT07085091

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid...

Sponsor: ALX Oncology Inc.Enrolling: 1707 locations
RECRUITINGPhase 1NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck,...

Sponsor: PfizerEnrolling: 31020 locations
RECRUITINGPhase 2 / Phase 3NCT06851663

Trop2-targeted immunoPET Imaging of Solid Tumors

This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging...

Sponsor: RenJi HospitalEnrolling: 4001 location
RECRUITINGPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of...

Sponsor: Daiichi SankyoEnrolling: 74020 locations
RECRUITINGPhase 3NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response...

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for...

Sponsor: UNICANCEREnrolling: 64620 locations
RECRUITINGNCT03958240

Deciphering Mechanisms Underlying Cancer Immunogenicity

This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T...

Sponsor: Institut Claudius RegaudEnrolling: 11003 locations
RECRUITINGPhase 1NCT07020117

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in...

Sponsor: Aktis Oncology, Inc.Enrolling: 1509 locations
RECRUITINGNCT06116019

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment...

Sponsor: Charite University, Berlin, GermanyEnrolling: 6491 location
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 2856 locations
RECRUITINGNCT06835426

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the...

Sponsor: Algemeen Ziekenhuis Maria MiddelaresEnrolling: 1501 location
RECRUITINGPhase 1NCT06673329

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects...

Sponsor: Brian Henick, MDEnrolling: 111 location
RECRUITINGPhase 1NCT07358806

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety...

Sponsor: Oscotec Inc.Enrolling: 513 locations
RECRUITINGPhase 1 / Phase 2NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation...

Sponsor: Perspective TherapeuticsEnrolling: 1127 locations
RECRUITINGPhase 1NCT06761937

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Patients with head and neck cancer treated with radiotherapy (RT) have a substantial change of recurrence of the tumor in the pharynx or lymph nodes in the neck. Once tumor and/or...

Sponsor: Erasmus Medical CenterEnrolling: 301 location
RECRUITINGNCT06307314

Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis

Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. At present,...

Sponsor: Nanfang Hospital, Southern Medical UniversityEnrolling: 3005 locations
RECRUITINGNCT07318220

Prehabilitation Protocol for Head and Neck Cancer Patients

The purpose of this research is to help researchers understand the barriers, supports, and preferences for prehabilitation. Prehabilitation in this study means head and neck...

Sponsor: University of MiamiEnrolling: 601 location
RECRUITINGNCT07160296

Supporting Treatment Resilience With Optimized Nutrition and Guided Exercise in Head and Neck Cancer Patients...

The purpose of this study to find out whether a structured lifestyle intervention-combining nutrition counseling, guided exercise, and wellness education-can help reduce...

Sponsor: Renown HealthEnrolling: 302 locations
RECRUITINGNCT05811936

The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

In this randomized behavioral intervention, head and neck cancer (HNC) survivors and their caregivers (N=176 HNC survivor-caregiver dyads) will be randomized to either...

Sponsor: Medical University of South CarolinaEnrolling: 3521 location
RECRUITINGEarly Phase 1NCT05553782

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in...

Sponsor: Brigham and Women's HospitalEnrolling: 302 locations

Frequently Asked Questions

There are currently 23 clinical trials for Head and Neck Cancer, with 23 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Head and Neck Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Head and Neck Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.